CYBERDYNE

CYBERDYNE occupies a specialized position at the intersection of rehabilitation medicine, wearable robotics, medical devices, and physical AI. Its central differentiation is the HAL platform, which detects faint bioelectric signals and uses the wearer’s movement intent to assist joint motion. That approach gives the company a stronger human-machine interface orientation than conventional industrial robotics providers, while its Cybernic Treatment model connects hardware with repeated therapeutic movement. The portfolio also includes Cyvis M100 vital sensing, Acoustic X photoacoustic imaging, and autonomous cleaning and transport robots, creating a broader healthcare-automation footprint than a single-product exoskeleton company. The company is publicly listed in Japan, has operated since 2004, and has reported deployments or approvals across more than 20 countries. The principal market constraints are likely clinical adoption, reimbursement, regulatory execution, installation economics, and the need to demonstrate outcomes across different healthcare systems. Its 2026 Pegasus partnership and ¥10 billion venture fund indicate an effort to extend this position through external AI relationships rather than relying solely on internally developed robotics.

CYBERDYNE’s trajectory shows a transition from a university-origin robotics venture into a listed, multi-product healthcare technology company. Founded by Yoshiyuki Sankai in 2004, it raised nine recorded rounds between 2007 and 2014 totaling $62.27 million, with notable venture financing of $26.99 million on Jun 30, 2011 and an additional $9.37 million on Jul 4, 2008. It went public on Mar 26, 2014 under ticker TYO:7779. More recently, growth has been expressed through product and ecosystem expansion rather than disclosed fundraising for the parent company. HAL-based rehabilitation services remain the core platform, while Cyvis M100 extends the business into cardiac monitoring and Acoustic X adds imaging capabilities. The 2025 launch activity around hospital disinfection robotics and HAL gait training suggests continued diversification, although the associated public descriptions have limited commercial detail. In 2026, the Pegasus Tech Ventures partnership and approximately ¥10 billion corporate venture capital fund created a new external growth channel focused on physical AI and Silicon Valley startups. The Malaysia rehabilitation center opening on Jun 17, 2026 provides evidence of international deployment. Employee growth, revenue growth, and unit economics remain undisclosed.